Aethlon Medical, Inc. (AEMD) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended December 31, 2024. Aethlon Medical, Inc. is a clinical-stage medical therapeutic company developing the Hemopurifier, an immunotherapeutic device designed to remove harmful exosomes and viruses from biological fluids. The device has received FDA "Breakthrough Device" designation for advanced/metastatic cancer and life-threatening viral infections. The company is currently conducting safety, feasibility, and dose-finding clinical trials in Australia and India.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2024 | Nine Months Ended Dec 31, 2024 | As of Dec 31, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(1,754,783) | $(7,133,196) | N/A |
| Operating Expenses | $1,814,747 | $7,337,402 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $4,825,387 |
| Working Capital | N/A | N/A | $3,194,737 |
| Accumulated Deficit | N/A | N/A | $(161,699,924) |
| Shares Outstanding | N/A | N/A | 13,986,669 |
Note: The company has no revenue. Operating expenses consist primarily of professional fees, payroll, and general/administrative costs. Interest income of $59,964 (3 months) and $204,206 (9 months) offset a portion of the net loss.
Material Changes vs. Prior Period
- Expense Reduction: Operating expenses decreased by 49.1% in the three months ended Dec 31, 2024, compared to the same period in 2023 ($1.81M vs. $3.57M). This was driven by a $1.3M decrease in payroll (due to headcount reduction and absence of prior CEO separation costs) and a $291k decrease in professional fees.
- Net Loss Improvement: Net loss for the three months ended Dec 31, 2024, was $(1.75M), a significant improvement from $(3.47M) in the prior year period.
- Capital Raising: In May 2024, the company closed a public offering raising approximately $4.7M gross ($3.5M net). Additionally, warrant exercises in June 2024 generated $1.84M in proceeds.
- Cash Position: Cash and cash equivalents decreased from $5.44M at March 31, 2024, to $4.83M at December 31, 2024, despite financing inflows, due to ongoing operational burn.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Existing cash is not sufficient to fund operations for the next 12 months. Additional debt or equity financing is required.
- Clinical Progress:
- Australia: Two hospitals (Royal Adelaide, Pindara) are open for enrollment. The first patient was treated in late January 2025 with no adverse events.
- India: Ethics approval received for Medanta Medicity Hospital. The COVID-19 trial in India was terminated in November 2024 due to lack of patient enrollment.
- Risks: Key risks include the inability to raise additional capital, delays in clinical trials, failure to obtain FDA approval, and potential delisting from Nasdaq if listing requirements are not met.
- Subsequent Events: In January and February 2025, additional warrant exercises generated approximately $210,000 in proceeds.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for the next capital raise given the "substantial doubt" disclosure and current cash burn rate.
- Clinical Enrollment: Monitor patient enrollment rates in the Australia and India oncology trials to assess the feasibility of the upcoming Premarket Approval (PMA) study.
- Warrant Overhang: Review the terms and expiration dates of the 13.3M+ outstanding warrants (Class A, Class B, and Placement Agent) which could impact future dilution.
- Related Party Liabilities: Note the $781,899 in amounts due to related parties, primarily accrued separation expenses and board fees.
- Internal Controls: Acknowledge the previously identified material weakness regarding segregation of duties in financial reporting, which management is currently remediating.